Panacea Biotec to make 100mn doses of Sputnik vax
May 24, 2021  17:06
India vaccinates with Covishield and Covaxin against Covid
India vaccinates with Covishield and Covaxin against Covid
Indian firm Panacea Biotec begins production of Sputnik V vaccines. It will annually manufacture 100 million doses of Sputnik V.  The first batch of the COVID-19 vaccine produced at Panacea Biotec's facilities at Baddi in Himachal Pradesh will be shipped to the Russia's Gamaleya Center for quality control. Full-scale production of the vaccine is expected to start this summer, RDIF and Panacea Biotec said in a joint statement. 

 As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V, it added. 

 "Launch of production in India in partnership with Panacea Biotec marks an important step in helping the country fight the pandemic," RDIF chief executive Kirill Dmitriev said. 

 The production of Sputnik V supports efforts of India's authorities to leave behind the acute phase of coronavirus as soon as possible while the vaccine will also be exported at a later stage to help prevent the spread of the virus in other countries around the world, he added.
« Back to LIVE

TOP STORIES